



Biocon Limited

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/34

June 24, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Dear Sir/ Madam,

Subject: Press Release

Please find enclosed the press release titled “**Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders**”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Press Release



PRESS RELEASE

Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders

Bengaluru, Karnataka, India and Johor, Malaysia – June 24, 2026

Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad (“Duopharma Biotech”) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year. As part of these contracts, Biocon’s subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia.

The contracts comprise a three-year agreement valued at ~MYR 155.27 million for human insulin, along with two 2-year agreements: ~MYR 18 million for insulin glargine and ~MYR 52.5 million for insulin aspart. In line with policies indicated in the 13th Malaysia Plan (“RMK-13”) and the New Industrial Master Plan 2030 (“NIMP 2030”), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said: *“Malaysia has been central to Biocon’s insulin journey for over a decade, anchored by our integrated insulin manufacturing facility in the country – the largest in Asia. Our Johor operations enable us to deliver insulin at scale, expanding patient access in Malaysia and around the world. This reinforces our strategy to address growing healthcare needs while advancing our mission of making life-changing medicines affordable and accessible to patients everywhere.”*

Joe Sian, Site Head, Biocon Sdn. Bhd., said: *“Biocon’s partnership with Duopharma Biotech has helped expand access to insulin therapies for patients in Malaysia. With an estimated 4.75 million¹ people living with diabetes in the country, ensuring affordable insulin supply is essential. This collaboration enables us to support patients across our full portfolio of insulin products.”*

Encik Wan Amir-Jeffery Wan Abdul Majid, GCEO, Duopharma Biotech Berhad, said: *“Duopharma Biotech is delighted and honoured to mark a decade in supporting the healthcare ecosystem together with our long-standing partner - Biocon, alongside welcoming new contracts to supply insulin products to Malaysian patients. It is more critical than ever to have robust domestic pharmaceutical manufacturing capacity to safeguard patient access to essential medicines, strengthening national medicine security and achieving healthcare self-reliance for the country.”*

¹ IDF Diabetes Atlas 11th edition



Biocon has been working with Duopharma Biotech since 2016 to address Malaysia's growing diabetes burden. Through this collaboration, over 120 million insulin cartridges have been supplied to the MoH facilities over the past decade, supporting more than 450,000 patients in the Malaysia public healthcare system. Beyond diabetes care, both companies have also worked closely in oncology for more than seven years and have recently expanded into ophthalmology biologics, further improving access to high-quality biologic therapies for patients across Malaysia.

About Biocon Sdn. Bhd.

Biocon Sdn. Bhd., a stepdown subsidiary of Biocon Limited, operates one of Asia's largest integrated insulin facilities for recombinant human insulin and insulin analog products. Located in Iskandar Puteri, Johor, Malaysia, the state-of-the-art facility has fully integrated capabilities spanning drug substance manufacturing and drug product fill-finish operations across vials, cartridges and insulin delivery devices. It manufactures a comprehensive portfolio of regular, long-acting and rapid-acting insulins for Malaysia and global markets.

The facility houses advanced R&D, Quality Assurance and Quality Control laboratories, supported by a robust Quality Management System that underpins global manufacturing and compliance standards. The site employs more than 1,100 personnel. Biocon has invested over USD 600 million in the facility since 2011 in this Center of Excellence for insulin manufacturing, representing one of the largest foreign direct investments (FDI) in Malaysia's biotechnology sector.

The facility has secured multiple global regulatory approvals, including from Malaysia's National Pharmaceutical Regulatory Agency (NPRA), Ireland's Health Products Regulatory Authority (HPRA) under the framework of the European Medicines Agency, U.S. Food and Drug Administration (U.S. FDA), Brazil's ANVISA and Australia's Therapeutic Goods Administration (TGA). It remains the only manufacturing facility in Malaysia approved by both the EMA and the U.S. FDA for sterile biologic products.

Biocon's investments in Malaysia have not only advanced the country's biotechnology sector but have also helped reduce Malaysia's dependency on imported insulin while contributing to improved access, greater affordability and enhanced price stability of insulin for patients across the country.

Recently, Biocon has partnered with the Malaysian government to contribute its industry expertise to the MyMAHIR BioTechies initiative, supporting the skilling of biotech graduates and helping bridge the academia-industry gap.

About Biocon Limited

Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world's most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook



2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: www.biocon.com Follow us on X: [@bioconlimited](https://twitter.com/bioconlimited) LinkedIn: [Biocon](https://www.linkedin.com/company/biocon)

About Duopharma Biotech Bhd.

Duopharma Biotech began with the establishment of Duopharma (M) Sdn Bhd in 1978. Duopharma Biotech was incorporated in 2000 and is today the leading pharmaceutical company listed on the Main Market of Bursa Malaysia Berhad and a pioneer in the halal pharmaceutical space.

Duopharma Biotech has core competencies in the pharmaceutical industry, including the research and development, manufacturing, marketing and commercialisation of over 300 generic drugs such as Caridine Syrup, Duocoxib, Varexa and Vytan as well as consumer healthcare products, including CHAMPS®, EYE GLO, FLAVETTES® and UPHAMOL®, which are well recognised and accepted by consumers in Malaysia, regionally and globally. The company has also diversified into the biosimilars space with technology and commercialisation collaborations with credible and strong international partners. ERYSAA®, Basalog One®, Zuhera, Krabeva® and Yesafili are a few commercialised biosimilar brands.

Headquartered in Kuala Lumpur, Malaysia, Duopharma Biotech owns and operates a research and development facility, and three manufacturing plants in Klang, Bangi and Glenmarie, Selangor. Duopharma Biotech also has subsidiary companies in the Philippines, Singapore and Indonesia.

FOR MORE INFORMATION (INDIA)	
<i>For Media</i> Rumman Ahmed Head – External Communications, Biocon +91 98451 04173 rumman.ahmed@biocon.com	<i>For Investors</i> Prashant Nair Head – Investor Relations, Biocon +91 98200 95476 prashant.nair@biocon.com